Cancer Biology and Metastasis
This group aims to explore the cooperation effect of the two most frequent onco-viruses in human carcinogenesis and metastasis using human cell line and animal models which were recently established in our previous laboratory. Meanwhile, we are planning to identify gene and microRNA signatures of triple negative and non-triple negative human breast cancer in the population of the Gulf countries using microarray technology, as demonstrated in our earlier works.
On the other hand, and based on our background, we are planning to develop a new “in vivo” model to identify gene signatures of metastatic cancer related to a specific organ using chicken embryo model; this model will be also used to explore toxicity effect of the new nanoparticles and advices on normal development."
PI: Professor Ala-Eddin Al Moustafa
Inflammation in the brain
This group uses in-vitro and in-vivo models to investigate the underlying mechanisms of inflammation in the brain and its role in the pathogenesis of neurodegeneration. Furthermore, the group investigates novel therapeutic approaches for the treatment of these neurological disorders.
The group aims to:
- Advance basic research in identifying biomarkers, like pro-inflammatory mediators that can be targeted for therapeutic intervention.
- Based on a new peptide identified by the group, explore the possibility of using novel molecule for clinical research, and the potential for phase II clinical trials.
PI: Professor Bared Safieh-Garabedian
Cancer Proteomics and systems biology for personalized medicine
This group focuses on study of carcinogenic transformation of human cells. We want to decipher mechanisms which transform normal cells into cancerous. We use acquired knowledge for improving diagnostic and treatment of human cancer, including practical clinical applications.
The group aims are:
- To describe molecular mechanisms governing development of cancer, by using proteomics, systems biology and signaling studies.
- To develop tools for diagnostic and personalization of cancer treatment.
PI: Professor Serhiy Souchelnytskyi